Nektar Therapeutics

LSE:0UNL Stock Report

Market Cap: US$164.5m

Nektar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:0UNL Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
24 Dec 24SellUS$14,738Mark WilsonIndividual16,560US$0.89
23 Dec 24SellUS$30,062Mark WilsonIndividual33,402US$0.90
19 Dec 24SellUS$48,048Jonathan ZalevskyIndividual51,115US$0.94
18 Dec 24SellUS$131,650Howard RobinIndividual132,030US$1.01
19 Nov 24SellUS$6,471Mark WilsonIndividual6,407US$1.01
19 Nov 24SellUS$7,863Jonathan ZalevskyIndividual7,785US$1.01
19 Nov 24SellUS$16,441Howard RobinIndividual16,278US$1.01
19 Aug 24SellUS$19,048Howard RobinIndividual14,881US$1.28
19 Aug 24SellUS$7,233Mark WilsonIndividual5,651US$1.28
19 Aug 24SellUS$8,788Jonathan ZalevskyIndividual6,866US$1.28
17 May 24SellUS$29,138Howard RobinIndividual16,650US$1.75
17 May 24SellUS$10,955Mark WilsonIndividual6,260US$1.75
17 May 24SellUS$12,871Jonathan ZalevskyIndividual7,355US$1.75
10 May 24SellUS$99,630Deep Track Capital, LPCompany56,000US$1.78
20 Feb 24SellUS$6,130Jonathan ZalevskyIndividual9,014US$0.68
20 Feb 24SellUS$13,622Howard RobinIndividual20,033US$0.68
20 Feb 24SellUS$5,172Mark WilsonIndividual7,606US$0.68

Insider Trading Volume

Insider Buying: 0UNL insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0UNL?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,710,2281.47%
VC/PE Firms15,922,6558.63%
General Public40,129,25521.8%
Institutions125,696,14668.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 67.32% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.66%
BlackRock, Inc.
15,969,345US$14.2m5.37%no data
8.63%
Deep Track Capital, LP
15,922,655US$14.2m-10.9%0.46%
7.11%
The Vanguard Group, Inc.
13,120,793US$11.7m1.18%no data
5.1%
Eventide Asset Management, LLC
9,400,000US$8.4m24.9%0.14%
4.99%
Samlyn Capital, LLC
9,199,951US$8.2m-2.73%0.13%
3.77%
Citadel Advisors LLC
6,954,970US$6.2m0%0.01%
3.21%
PRIMECAP Management Company
5,912,453US$5.3m-1.79%no data
3.07%
Acadian Asset Management LLC
5,654,878US$5.0m15.8%0.01%
2.74%
Millennium Management LLC
5,061,719US$4.5m8.63%no data
2.23%
Nantahala Capital Management, LLC
4,110,000US$3.7m0%0.29%
2.17%
TCG Crossover Management, LLC
4,000,000US$3.6m0%0.37%
2.15%
Geode Capital Management, LLC
3,963,083US$3.5m-3.63%no data
1.81%
State Street Global Advisors, Inc.
3,345,733US$3.0m11.9%no data
1.8%
Renaissance Technologies LLC
3,327,633US$3.0m0.42%no data
1.51%
Jacobs Levy Equity Management Inc
2,793,204US$2.5m-2.78%0.01%
1.08%
Monaco Asset Management S.A.M.
1,997,220US$1.8m-7.81%0.71%
0.94%
Woodline Partners LP
1,731,671US$1.5m178%0.01%
0.94%
Goldman Sachs Group, Investment Banking and Securities Investments
1,726,557US$1.5m-2.32%no data
0.86%
Shay Capital LLC
1,595,276US$1.4m-13.3%0.38%
0.81%
Two Sigma Advisers, LP
1,500,242US$1.3m-18.3%no data
0.79%
Charles Schwab Investment Management, Inc.
1,454,168US$1.3m0%no data
0.76%
Northern Trust Global Investments
1,402,158US$1.3m212%no data
0.74%
Two Sigma Investments, LP
1,363,170US$1.2m-24.7%no data
0.74%
Bridgeway Capital Management, LLC
1,362,100US$1.2m0%0.02%
0.71%
Ikarian Capital, LLC
1,312,405US$1.2m0%0.36%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 03:26
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nektar Therapeutics is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Aydin HuseynovBenchmark Company
George FarmerBMO Capital Markets Equity Research